Northern Lights Fund Trust - Agility Shares Managed Risk ETF (MRSK) Stock Price

36.77 ▼ -0.05 (-0.14%)
Open: 36.565 Vol: 0 Day's range: 36.565 - 37.01 Feb 13, 15:59 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
MRSK Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 36.81▼ 36.88▼ 36.82▼ 37.09▼ 37.10▼
MA10 36.85▼ 36.87▼ 36.93▼ 37.05▼ 37.09▼
MA20 36.92▼ 37.10▼ 37.13▼ 37.12▼ 36.57▲
MA50 37.05▼ 37.09▼ 37.10▼ 37.01▼ 34.53▲
MA100 37.16▼ 37.10▼ 37.11▼ 36.50▲ 33.37▲
MA200 37.14▼ 36.99▼ 36.76▲ 35.08▲ 31.40▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.013▼ -0.029▼ -0.039▼ -0.050▼ -0.089▼
RSI 42.239▼ 41.644▼ 42.338▼ 44.451▼ 57.145▲
STOCH 53.978     46.566     28.801     57.688     79.604    
WILL %R -53.933     -73.548     -73.548     -77.345▼ -32.857    
CCI -56.217     -105.192▼ -100.222▼ -126.356▼ 28.348    
Latest Filters Detected On MRSK
▼ MACD $MRSK MACD(12,26,9) Crossed Below Zero Set Alert
Northern Lights Fund Trust - Agility Shares Managed Risk ETF News
Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+
Friday, February 13, 2026 07:27 AM
Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and ...
Merck’s Ovarian Cancer Wins Tested Against Valuation Gap And Momentum
Thursday, February 12, 2026 03:32 AM
Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its subcutaneous formulation QLEX for platinum-resistant ovarian cancer. The FDA also approved a companion diagnostic to help identify patients ...
FDA clears Merck’s Keytruda and Keytruda QLEX for platinum-resistant ovarian cancer
Wednesday, February 11, 2026 07:19 AM
The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat ...
MRSK historical stock data
date open high low close volume
13/02/26 36.565 37.01 36.565 36.77 29,877
12/02/26 37.23 37.24 36.82 36.82 13,009
11/02/26 37.4099 37.4099 37.22 37.33 16,770
10/02/26 37.48 37.48 37.24 37.26 26,696
09/02/26 37.2545 37.45 37.2545 37.29 29,448
06/02/26 36.961 37.20 36.84 37.13 25,100
05/02/26 36.55 36.745 36.5181 36.53 28,128
04/02/26 37.06 37.12 36.811 36.988 91,100
03/02/26 37.46 37.46 36.92 37.07 40,500
02/02/26 37.03 37.51 37.03 37.33 31,570
Quote Details
52wk Low:28.28
52wk High:37.69
Vol:0
Avg Vol(3m):712K
1Y Chng:+11.83%
1M Chng:-0.27%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00